About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: GLPG
- Previous Close: $69.80
- 50 Day Moving Average: $67.28
- 200 Day Moving Average: $61.66
- 52-Week Range: $39.63 - $73.37
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -40.11
- P/E Growth: 0.00
- Market Cap: $3.22B
- Beta: 1.85
- Net Margins: -67.15%
- Return on Equity: -8.23%
- Return on Assets: -5.78%
Companies Related to Galapagos NV:
- Current Ratio: 7.42%
- Quick Ratio: 7.42%
Earnings History for Galapagos NV (NASDAQ:GLPG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS
Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Galapagos NV (NASDAQ:GLPG)
What is Galapagos NV's stock symbol?
Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."
Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?
6 brokers have issued twelve-month price objectives for Galapagos NV's shares. Their forecasts range from $48.00 to $89.00. On average, they expect Galapagos NV's stock price to reach $66.50 in the next year.
What are analysts saying about Galapagos NV stock?
Here are some recent quotes from research analysts about Galapagos NV stock:
According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (1/31/2017)
Cowen and Company analysts commented, "Galapagos reported positive data from the SAPHIRA1 trial of GLPG1837 in G551D CF." (12/23/2016)
Janney Montgomery Scott analysts commented, "interesting paradigm" in the management of Rheumatoid Arthritis (RA). Thus, in Filgotinib (partnered with Gilead), Galapagos has a "potential blockbuster."The Filgotinib Advantage"We are modeling peak sales of $1.9 billion for filgotinib in RA, and $658 million in Crohn's with Ulcerative Colitis offers additional optionality (not in our FV)," analyst Debjit Chattopadhyay wrote in a note.Chattopadhyay acknowledges that Filgotinib is at least two years behind Baricitinib, an RA drug from Incyte Corporation (NASDAQ: INCY) and Eli Lilly and Co (NYSE: LLY).Related Link: Here Are All The Big Biotech Mergers In 2016However, since the company's drug is third in to launch, it may be a commercial positive, because experience from Pfizer Inc. (NYSE: PFE)'s Xeljanz suggests physicians are likely to become increasingly more comfortable with the safety profile of JAK inhibitors over the next two years."Filgotinib JAK1 specificity resulting in a superior hematologic safety profile over competitors could be an advantage (more so in IBD); oral dosing increases convenience over biologics; and although experience with GILD suggests otherwise, filgotinib could be priced attractively vs. other JAK's and biosimilars (we are modeling a $21,000 launch price in U.S.)," Chattopadhyay noted.Cystic FibrosisMeanwhile, the analyst highlighted that Cystic Fibrosis corrector/potentiator commercial opportunity could exceed $7 billion globally, and he assumes a 30 percent market share for Galapagos/AbbVie.Currently, Vertex is the leader in Cystic Fibrosis market with its Kalydeco and Orkambi. The analyst noted that with about 70,000 patient commercial opportunities, it may not be feasible for Galapagos to develop a potentiator and corrector sequentially, especially if Vertex's triple-combo succeeds in meaningfully improving upon Orkambi."Whether GLPG/ABBV will choose a phase 3 program prior to a triple-combo phase 2 is not yet clear, but will likely be data dependent. Either way, progress on the CF program will be a key driver of sentiment on GLPG stock over the next 12 to 18 months, in our view," (8/30/2016)
Who owns Galapagos NV stock?
Galapagos NV's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.02%), Federated Investors Inc. PA (2.39%), EcoR1 Capital LLC (1.22%), Deerfield Management Co. (0.92%), Perceptive Advisors LLC (0.66%) and Orbimed Advisors LLC (0.61%).
Who sold Galapagos NV stock? Who is selling Galapagos NV stock?
Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC and Clough Capital Partners L P.
Who bought Galapagos NV stock? Who is buying Galapagos NV stock?
Galapagos NV's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Renaissance Technologies LLC, EcoR1 Capital LLC, Employees Retirement System of Texas, FMR LLC, Castleark Management LLC and Marshall Wace LLP.
How do I buy Galapagos NV stock?
Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Galapagos NV stock cost?
One share of Galapagos NV stock can currently be purchased for approximately $69.80.
Galapagos NV (NASDAQ:GLPG) Chart for Tuesday, February, 21, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart